Comments
Cadila Healthcare Ltd (Zydus Cadila) and its subsidiary Zydus Pharmaceuticals (USA) Inc on Thursday announced that they have entered into a settlement and license agreement with Somaxon Pharmaceuticals, Inc. and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.
According to a company statement here, Cadila Healthcare and Zydus Pharmaceuticals will now have the right to begin selling a generic version of Silenor 180 days after another party begins selling its generic version in the US. This will be under a license from Somaxon, 180 days after a United States court enters a final decision that Somaxon's patents are not infringed, invalid or unenforceable, or earlier under certain circumstances, the release said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.